Technical Analysis for SGYP - Synergy Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.03 -52.00% -0.03
SGYP closed down 52.0 percent on Thursday, March 7, 2019, on 2.8 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SGYP trend table...

Date Alert Name Type % Chg
Mar 7 New 52 Week Closing Low Bearish 0.00%
Mar 7 Reversal New Lows Setup Bearish Swing Setup 0.00%
Mar 7 New 52 Week Low Weakness 0.00%
Mar 7 Earnings Movers Other 0.00%
Mar 7 Wide Bands Range Expansion 0.00%
Mar 7 Oversold Stochastic Weakness 0.00%
Mar 6 Calm After Storm Range Contraction -52.00%
Mar 6 Narrow Range Bar Range Contraction -52.00%
Mar 6 NR7 Range Contraction -52.00%
Mar 6 Wide Bands Range Expansion -52.00%

Older signals for SGYP ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate includes plecanatide, a guanylyl cyclase C receptor agonist that has completed Phase IIa clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase I clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Medicine Biopharmaceutical Medical Specialties Diseases Autoimmune Diseases Disorders Ulcerative Colitis Gastroenterology Abdominal Pain Irritable Bowel Syndrome Gastrointestinal Tract Functional Constipation Linaclotide
Is SGYP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.22
52 Week Low 0.03
Average Volume 17,611,571
200-Day Moving Average 1.0802
50-Day Moving Average 0.2382
20-Day Moving Average 0.2073
10-Day Moving Average 0.1169
Average True Range 0.0396
ADX 31.6
+DI 10.5938
-DI 42.1765
Chandelier Exit (Long, 3 ATRs ) 0.2312
Chandelier Exit (Short, 3 ATRs ) 0.1488
Upper Bollinger Band 0.4261
Lower Bollinger Band -0.0115
Percent B (%b) 0.09
BandWidth 211.095031
MACD Line -0.0666
MACD Signal Line -0.0436
MACD Histogram -0.0229
Fundamentals Value
Market Cap 6.75 Million
Num Shares 225 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -0.03
Price-to-Sales 246.22
Price-to-Book 13.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.08
Resistance 3 (R3) 0.09 0.08 0.07
Resistance 2 (R2) 0.08 0.06 0.07 0.07
Resistance 1 (R1) 0.05 0.06 0.05 0.05 0.07
Pivot Point 0.04 0.04 0.04 0.04 0.04
Support 1 (S1) 0.02 0.03 0.01 0.01 -0.01
Support 2 (S2) 0.01 0.02 0.00 -0.01
Support 3 (S3) -0.02 0.01 -0.01
Support 4 (S4) -0.02